-
公开(公告)号：US6136525A
公开(公告)日：2000-10-24
申请号：US364893
申请日：1999-08-02
申请人： Claudy Jean-Paul Mullon , Shawn Paul Cain , Timothy Jon Perlman , Hugo O. Jauregui , Sharda Naik , Henry A. Santangini , Donna M. Trenkler
发明人： Claudy Jean-Paul Mullon , Shawn Paul Cain , Timothy Jon Perlman , Hugo O. Jauregui , Sharda Naik , Henry A. Santangini , Donna M. Trenkler
CPC分类号： A61L27/3804 , A01N1/02 , A01N1/0221 , A01N1/0226 , A01N1/0268 , A01N1/0284 , A61L27/3839 , A61L27/3895
摘要： An artificial liver support system is described herein which comprises cryopreserved hepatocytes having an initial viability of 80-99%. Further disclosed are hepatocytes cryopreserved by dispensing hepatocytes into freezing containers, freezing the containers from between minus 50 to minus 90 degrees Celsius, storing the containers in liquid or vapor nitrogen, thawing the cryopreserved hepatocytes when ready for use and removing residual cryoprotectant media.
摘要翻译： 本文描述了一种人造肝支持系统，其包括具有80-99％的初始存活率的冷冻保存的肝细胞。 进一步公开的是通过将肝细胞分配到冷冻容器中冷冻保存的肝细胞，将容器从零下50至零摄氏度之间冷冻，将容器储存在液体或蒸气氮中，在准备使用时解冻冷冻保存的肝细胞并除去残留的冷冻保护剂介质。
-
公开(公告)号：US5795711A
公开(公告)日：1998-08-18
申请号：US627446
申请日：1996-04-04
申请人： Claudy Jean-Paul Mullon , Shawn Paul Cain , Timothy Jon Perlman , Hugo O. Jauregui , Sharda Naik , Henry A. Santangini , Donna M. Trenkler
发明人： Claudy Jean-Paul Mullon , Shawn Paul Cain , Timothy Jon Perlman , Hugo O. Jauregui , Sharda Naik , Henry A. Santangini , Donna M. Trenkler
CPC分类号： A61L27/3804 , A01N1/02 , A01N1/0221 , A01N1/0226 , A01N1/0268 , A01N1/0284 , A61L27/3839 , A61L27/3895
摘要： An artificial liver support system is described herein which comprises cryopreserved hepatocytes having an initial viability of 80-99% and a metabolic activity 50-80% of fresh hepatocytes. Further disclosed are hepatocytes cryopreserved by dispensing hepatocytes into freezing containers, freezing the containers from between minus 50 to minus 90 degrees Celsius, storing the containers in liquid or vapor nitrogen, thawing the cryopreserved hepatocytes when ready for use and removing residual cryoprotectant media.
摘要翻译： 本文描述了一种人造肝支持系统，其包含具有80-99％的初始存活率和新鲜肝细胞的代谢活性50-80％的冷冻保存的肝细胞。 进一步公开的是通过将肝细胞分配到冷冻容器中冷冻保存的肝细胞，将容器从零下50至零摄氏度之间冷冻，将容器储存在液体或蒸气氮中，在准备使用时解冻冷冻保存的肝细胞并除去残留的冷冻保护剂介质。
-
3.发明授权Methods and apparatus for creating particle derivatives of HDL with reduced lipid content 有权用于产生脂质含量降低的HDL颗粒衍生物的方法和装置公开(公告)号：US07361739B2
公开(公告)日：2008-04-22
申请号：US10996570
申请日：2004-11-23
申请人： Marc Bellotti , H. Bryan Brewer, Jr. , Hassibullah Akeefe , Adam Paul Conner , Timothy Jon Perlman
发明人： Marc Bellotti , H. Bryan Brewer, Jr. , Hassibullah Akeefe , Adam Paul Conner , Timothy Jon Perlman
IPC分类号： C07K1/00
CPC分类号： G01N33/92 , A61K9/1275 , A61K38/1709 , C07K14/775 , A61K2300/00
摘要： The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.
摘要翻译： 本发明涉及用于产生HDL的至少一种形式的衍生物而不显着影响LDL的系统，装置和方法。 HDL的这些衍生物是具有降低的脂质含量的颗粒，特别是降低的胆固醇含量。 这些颗粒具有结合胆固醇的能力，并且给予患者以增强细胞，胆固醇的流出并降低细胞，组织，器官和血管中的胆固醇水平。 本发明方法可用于治疗动脉粥样化性血管疾病，并且可与其他治疗如他汀类，胆固醇吸收抑制剂，烟酸，抗炎药，运动和饮食限制组合。
-
4.发明授权Methods and apparatus for creating particle derivatives of HDL with reduced lipid content 有权用于产生脂质含量降低的HDL颗粒衍生物的方法和装置公开(公告)号：US08637460B2
公开(公告)日：2014-01-28
申请号：US13601131
申请日：2012-08-31
申请人： Marc Bellotti , H. Bryan Brewer, Jr. , Hassibullah Akeefe , Adam Paul Conner , Timothy Jon Perlman
发明人： Marc Bellotti , H. Bryan Brewer, Jr. , Hassibullah Akeefe , Adam Paul Conner , Timothy Jon Perlman
CPC分类号： C07K14/775 , A61K9/1275 , A61K31/685 , A61K38/1709 , B01D11/0492 , B01D15/00 , B01D15/426 , G01N33/92 , A61K2300/00
摘要： The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.
摘要翻译： 本发明涉及用于产生HDL的至少一种形式的衍生物而不显着影响LDL的系统，装置和方法。 HDL的这些衍生物是具有降低的脂质含量的颗粒，特别是降低的胆固醇含量。 这些颗粒具有结合胆固醇的能力，并且给予患者以增强细胞，胆固醇的流出并降低细胞，组织，器官和血管中的胆固醇水平。 本发明方法可用于治疗动脉粥样化性血管疾病，并且可与其他治疗如他汀类，胆固醇吸收抑制剂，烟酸，抗炎药，运动和饮食限制组合。
-
5.发明授权Methods and apparatus for creating particle derivatives of HDL with reduced lipid content 有权用于产生脂质含量降低的HDL颗粒衍生物的方法和装置公开(公告)号：US08268787B2
公开(公告)日：2012-09-18
申请号：US13222287
申请日：2011-08-31
申请人： Marc Bellotti , H. Bryan Brewer, Jr. , Hassibullah Akeefe , Adam Paul Conner , Timothy Jon Perlman
发明人： Marc Bellotti , H. Bryan Brewer, Jr. , Hassibullah Akeefe , Adam Paul Conner , Timothy Jon Perlman
CPC分类号： C07K14/775 , A61K9/1275 , A61K31/685 , A61K38/1709 , B01D11/0492 , B01D15/00 , B01D15/426 , G01N33/92 , A61K2300/00
摘要： The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.
摘要翻译： 本发明涉及用于产生HDL的至少一种形式的衍生物而不显着影响LDL的系统，装置和方法。 HDL的这些衍生物是具有降低的脂质含量的颗粒，特别是降低的胆固醇含量。 这些颗粒具有结合胆固醇的能力，并且给予患者以增强细胞，胆固醇的流出并降低细胞，组织，器官和血管中的胆固醇水平。 本方法可用于治疗动脉粥样硬化性血管疾病，并可与其他疗法（如他汀类药物，胆固醇吸收抑制剂，烟酸，抗炎药，运动和饮食限制）结合使用。
-
6.发明申请公开(公告)号：US20080234621A1
公开(公告)日：2008-09-25
申请号：US12054162
申请日：2008-03-24
CPC分类号： G01N33/92 , A61K9/1275 , A61K38/1709 , C07K14/775 , A61K2300/00
摘要： The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.
-
7.发明申请公开(公告)号：US20080214438A1
公开(公告)日：2008-09-04
申请号：US12042924
申请日：2008-03-05
IPC分类号： A61K38/02
CPC分类号： G01N33/92 , A61K9/1275 , A61K38/1709 , C07K14/775 , A61K2300/00
摘要： The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.
-
8.发明授权公开(公告)号：US08048015B2
公开(公告)日：2011-11-01
申请号：US12054162
申请日：2008-03-24
申请人： Marc Bellotti , H. Bryan Brewer, Jr. , Hassibullah Akeefe , Adam Paul Conner , Timothy Jon Perlman
发明人： Marc Bellotti , H. Bryan Brewer, Jr. , Hassibullah Akeefe , Adam Paul Conner , Timothy Jon Perlman
CPC分类号： G01N33/92 , A61K9/1275 , A61K38/1709 , C07K14/775 , A61K2300/00
摘要： The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.
-
9.发明授权Methods and apparatus for creating particle derivatives of HDL with reduced lipid content 有权用于产生脂质含量降低的HDL颗粒衍生物的方法和装置公开(公告)号：US08030281B2
公开(公告)日：2011-10-04
申请号：US12042881
申请日：2008-03-05
申请人： Marc Bellotti , H. Bryan Brewer, Jr. , Hassibullah Akeefe , Adam Paul Conner , Timothy Jon Perlman
发明人： Marc Bellotti , H. Bryan Brewer, Jr. , Hassibullah Akeefe , Adam Paul Conner , Timothy Jon Perlman
CPC分类号： C07K14/775 , A61K9/1275 , A61K31/685 , A61K38/1709 , B01D11/0492 , B01D15/00 , B01D15/426 , G01N33/92 , A61K2300/00
摘要： The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.
摘要翻译： 本发明涉及用于产生HDL的至少一种形式的衍生物而不显着影响LDL的系统，装置和方法。 HDL的这些衍生物是具有降低的脂质含量的颗粒，特别是降低的胆固醇含量。 这些颗粒具有结合胆固醇的能力，并且给予患者以增强细胞，胆固醇的流出并降低细胞，组织，器官和血管中的胆固醇水平。 本发明方法可用于治疗动脉粥样化性血管疾病，并且可与其他治疗如他汀类，胆固醇吸收抑制剂，烟酸，抗炎药，运动和饮食限制组合。
-
10.发明申请Methods and Apparatus for Creating Particle Derivatives of HDL with Reduced Lipid Content 有权用于创建具有降低的脂质含量的HDL的颗粒衍生物的方法和装置公开(公告)号：US20080227726A1
公开(公告)日：2008-09-18
申请号：US12042881
申请日：2008-03-05
IPC分类号： A61K38/17
CPC分类号： C07K14/775 , A61K9/1275 , A61K31/685 , A61K38/1709 , B01D11/0492 , B01D15/00 , B01D15/426 , G01N33/92 , A61K2300/00
摘要： The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.
摘要翻译： 本发明涉及用于产生HDL的至少一种形式的衍生物而不显着影响LDL的系统，装置和方法。 HDL的这些衍生物是具有降低的脂质含量的颗粒，特别是降低的胆固醇含量。 这些颗粒具有结合胆固醇的能力，并且给予患者以增强细胞，胆固醇的流出并降低细胞，组织，器官和血管中的胆固醇水平。 本发明方法可用于治疗动脉粥样化性血管疾病，并且可与其他治疗如他汀类，胆固醇吸收抑制剂，烟酸，抗炎药，运动和饮食限制组合。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.039 秒)
